TIDMMEDG 
 
RNS Number : 3008N 
Medgenics Inc 
09 June 2010 
 

                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
9 June 2010 
 
The Board of Medgenics announces that on 8 June 2010 it was notified that Mr. 
Joel Kanter (a Director of the Company) had, on 1 June 2010, entered into a 
contract to transfer an RS warrant in respect of 14,080,734 common shares of US$ 
0.0001 each ("Common Shares") exercisable at a price of US $0.0005 per Common 
Share (the "Warrants"). The transaction was completed on 7 June 2010 and the 
Warrants were transferred for an aggregate price of US $240,000 to Chicago 
Investments, Inc ("CII"). 
 
CII is a majority-owned subsidiary of Chicago Holdings, Inc. ("CHI"). CHI is 
majority owned by various trusts (together the "Kanter Trusts") established for 
the benefit of various descendants of (i) Helen and Henry Krakow, and (ii) 
Beatrice and Morris Kanter. Joel Kanter is a discretionary beneficiary of some, 
but not all, of the Kanter Trusts. Sole voting and investment control of the 
Common Shares owned by CII (including Common Shares held by CII following an 
exercise of any of the Warrants) is vested in Mr. Kanter's brother, Joshua 
Kanter, as President of CII. 
 
The total interest in Shares, warrants and options of Joel Kanter is unchanged 
as a result of this transfer as the warrants held by CII are deemed to be 
included within his interests. 
 
For further information, contact: 
 
Andrew Pearlman                                             +972 4 902 8900 
CEO 
Medgenics, Inc 
 
Mike Wort / Anna Dunphy                                 +44 207 861 3838 
De Facto Communications (PR) 
 
James Pinner / Derek Crowhurst                       +44 207 444 0800 
Religare Capital Markets  (Nomad) 
 
Ian Callaway / Alex Mattey                               +44 207 638 5600 
SVS Securities plc (Joint Broker) 
 
Jonathan Senior                                                 +44 207 776 1219 
Nomura Code (Joint Broker) 
 
 
Notes to Editors: 
About Medgenics: 
Medgenics is a commercial -stage biopharmaceutical Company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The first revenue 
generating commercial deal with a well known multinational pharmaceutical 
company was negotiated in late 2009 and we look forward to generating additional 
deals to further commercialise the Biopump platform technology. 
Biopumps are made using needle biopsies taken from the lower layer of the 
patient's skin under local anaesthetic, and processed during 10-14 days to 
become 30 mm long tissue biofactories producing the required protein.  The 
requisite number of Biopumps are injected under the patient's skin to provide 
sustained protein production and delivery for many months. The Company is 
developing the Biopump to provide substantially greater safety and reliability 
in protein treatment in a more cost effective manner than experienced with the 
existing injected protein therapies.  Medgenics currently has three products in 
development based on this technology and addressing the indications of: 
 
 - Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Haemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effective anaemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anaemia, Hepatitis-C, and 
Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by 2010. Other potential 
applications of Biopumps producing various proteins include multiple sclerosis, 
arthritis, pediatric growth hormone deficiency, obesity, and diabetes. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSEASKNEDNEEEF
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Medgenics(Regs) Charts.